Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innate Pharma
Biotech
Sobi pens $580M deal for Innate’s cancer drug before ph. 3 push
Sobi has handed the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
James Waldron
Aug 10, 2026 7:13am
Innate's NK cell engager latest victim of pipeline refocus
Mar 26, 2026 5:20am
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
Sep 19, 2025 8:30am
Innate loses 30% of workforce in focus on 'highest-value assets'
Sep 17, 2025 5:16am
Innate says lymphoma data shows anti-KIR3DL2 antibody’s promise
May 23, 2025 5:13am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
